Formulation Development Forum: Nanosponges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation Development Forum: Nanosponges
Nanosponges, a controlled-release nanoparticle system, shows promise in targeted drug delivery


Pharmaceutical Technology
Volume 35, Issue 5, pp. 56-60


Patricia Van Arnum
Creating or improving systems for targeted drug delivery is an area of ongoing research, and is an area of particular importance to delivering anticancer therapeutics. Researchers at Vanderbilt University and Emory University recently reported on a controlled-release nanoparticle drug-delivery system, which may be an improved delivery method for delivering anticancer therapies, including direct injection into a tumor site.

The system, dubbed a "nanosponge," uses a nanoparticle-sized system to deliver the drug payload. These nanoparticles circulate in the body until they encounter the surface of a tumor cell, where they adhere to the surface and begin releasing the drug in a controllable and predictable fashion. The controlled-release nanoparticle drug-delivery system used a targeting peptide that recognized a radiation-induced cell-surface receptor. This targeting agent combined a recombinant peptide with a paclitaxel-encapsulating nanoparticle that specifically targeted irradiated tumors, thereby increasing apoptosis and tumor-growth delay. A Phage display biopanning identified Gly-Ile-Arg-Leu-Arg-Gly (GIRLRG) as a peptide that selectively recognizes GPR78, a receptor on certain tumor cells. Antibodies to GRP78 blocked the binding of GIRLRG in vitro and in vivo. The conjugation of GIRLRG to a sustained-release nanoparticle drug-delivery system increased paclitaxel concentration and apoptosis (1)

When loaded with an anticancer drug, the delivery system is three to five times more effective than direct injection at reducing tumor growth (2). The sponge acts as a three-dimensional network or scaffold. The backbone is a long-length polyester. It is mixed in solution with crosslinkers to form the polymer. The net effect is to form spherically shaped particles filled with cavities where drug molecules can be stored. The polyester is biodegradable, so it breaks down gradually in the body. As it breaks down, it releases its drug payload in a predictable fashion (2).

Targeted delivery systems of this type have several basic advantages. Because the drug is released at the tumor site instead of circulating widely through the body, it should be more effective for a given dosage. It also should have fewer harmful side effects because smaller amounts of the drug come into contact with healthy tissue. Another advantage is that the nanosponge particles are soluble in water. Encapsulating the anticancer drug in the nanosponge allows the use of hydrophobic drugs that do not dissolve readily in water. Currently, these drugs must be mixed with adjuvant reagents, which potentially can reduce the efficacy of the drug or cause side effect (2).

The nanosponge is produced through fairly simple chemistry. The researchers developed simple, high-yield so-called "click chemistry" methods for making the nanosponge particles and for attaching the linkers. The drug used for the animal studies was paclitaxel, the active ingredient in the anticancer therapy Taxol. The researchers recorded the response of two different tumor types—slow-growing human breast cancer and fast-acting mouse glioma—to single injections. In both cases, they found that the delivery through nanosponges increased the death of cancer cells and delayed tumor growth compared with other chemotherapy approaches.

Sources

1. E. Harth et al. Can. Res 70 (11), 4550–4559 (2010).

2. D. Salisbury, Exploration: Research News at Vanderbilt University, June 1, 2010.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here